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Alnumycin A is an aromatic pyranonaphthoquinone (PNQ) polyketide closely related 
to the model compound actinorhodin. While some PNQ polyketides are glycosylated, 
alnumycin A contains a unique sugar-like dioxane moiety. This unusual structural feature 
made alnumycin A an interesting research target, since no information was available 
about its biosynthesis. Thus, the main objective of the thesis work became to identify the 
steps and the enzymes responsible for the biosynthesis of the dioxane moiety.
Cloning, sequencing and heterologous expression of the complete alnumycin gene cluster 
from Streptomyces sp. CM020 enabled the inactivation of several alnumycin biosynthetic 
genes	 and	 preliminary	 identification	 of	 the	 gene	 products	 responsible	 for	 pyran	 ring	
formation, quinone formation and dioxane biosynthesis. The individual deletions of the 
genes resulted in the production of several novel metabolites, which in many cases turned 
out to be pathway intermediates and could be used for stepwise enzymatic reconstruction 
of the complete dioxane biosynthetic pathway in vitro. Furthermore, the in vitro reactions 
with	purified	alnumycin	biosynthetic	enzymes	resulted	in	the	production	of	other	novel	
compounds, both pathway intermediates and side products. 
Identification	and	molecular	level	studies	of	the	enzymes	AlnA	and	AlnB	catalyzing	the	
first	step	of	dioxane	biosynthesis	–	an	unusual	C-ribosylation	step	–	led	to	a	mechanistic	
proposal for the C-ribosylation of the polyketide aglycone. The next step on the dioxane 
biosynthetic pathway was found to be the oxidative conversion of the attached ribose 
into a highly unusual dioxolane unit by Aln6 belonging to an uncharacterized protein 
family, which unexpectedly occurred without any apparent cofactors. Finally, the last 
step of the pathway was found to be catalyzed by the NADPH-dependent reductase 
Aln4, which is able to catalyze the conversion of the formed dioxolane into a dioxane 
moiety. 
The work presented here and the knowledge gained of the enzymes involved in dioxane 
biosynthesis enables their use in the rational design of novel compounds containing C–C 
bound ribose, dioxolane and dioxane moieties.
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aa = amino acid
ACP = acyl carrier protein
CoA = coenzyme A
DHPA = 1,6-dihydroxy-8-propylanthraquinone
DNPA = 4-dihydro-9-hydroxy-1-methyl-10-oxo-3-H-naphtho[2,3-c]pyran-3-acetic acid
HPLC = high-performance liquid chromatography
KS = ketosynthase, ketoacyl synthase
MAT = malonyl–CoA:ACP transacylase
minPKS = minimal polyketide synthase
NDP = nucleoside diphosphate
NMR = nuclear magnetic resonance
ORF = open reading frame
PCR = polymerase chain reaction






The soil-dwelling bacterial species of the genus Streptomyces are well known for 
their production of a wide range of antimicrobial compounds. These Gram-positive, 
filamentous	bacteria	are	saprophytes,	and	morphologically	adapted	to	life	in	soil.	Their	
life cycle includes germination of spores, growth of mycelia and formation of aerial 
hyphae, which later develop into spores, thus completing the cycle. The synthesis of 
bioactive compounds against competing organisms only occurs under certain nutritional 
conditions	and	at	a	specific	growth	phase	and	morphological	stage,	often	as	a	response	
to starvation (Bibb 1996, Hopwood 2007). 
The importance of Streptomyces species as producers of medicinally useful compounds 
was	 already	 recognized	 in	 the	 1940s,	 when	 the	 first	 effective	 treatment	 against	
tuberculosis – the aminoglycoside antibiotic streptomycin – was discovered. This 
discovery,	together	with	an	earlier	finding	of	the	β-lactam	antibiotic	penicillin	produced	
by a fungal species, started the era of antibiotics. Streptomyces species still continue 
to be an important source of various medicinally useful compounds and antibiotics in 
particular; approximately two-thirds of the medicinally used antimicrobial agents are 
natural products of Streptomyces species, or their semisynthetic derivatives (Hopwood 
2007). 
A major concern related to the use of antibiotics is the ability of the target microbes to 
develop	resistance,	which	was	noticed	early	on	after	the	first	important	antibiotics	had	
found medicinal use. Resistance to antibiotics still remains a problem, and it is one of the 
driving forces in the search for novel biologically active compounds. As Streptomyces 
species and related bacteria have evolved to produce bioactive compounds, they continue 
to be an important source of potential new drug leads (Bérdy 2012). Knowledge of 
the antibiotic biosynthetic pathways of Streptomyces species and detailed mechanistic 
understanding of the enzymes catalyzing the biosynthetic steps set the ground for the 
controlled design of novel natural products. 
The	thesis	work	focused	on	the	identification	of	the	biosynthetic	enzymes	responsible	
for the formation of a unique dioxane moiety of a type II polyketide alnumycin A. 
Characterization of the alnumycin biosynthetic pathway involved studies on unusual 
enzymatic activities and reaction mechanisms encountered during the project, as well 
as structural analysis of both the biosynthetic enzymes and the novel natural products 
produced by them.
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2 LIteRAtURe RevIew
2.1 the polyketide class of natural products
The polyketide class of compounds is one of the major classes of medicinally used 
secondary metabolites of Streptomyces and related species of the order Actinomycetales. 
Important polyketides produced by these species include antibiotics (amphotericin B, 
erythromycin, rifamycins, tetracyclines), antiparasite drugs (avermectin), anticancer 
drugs (doxorubicin) and immunosuppressants (rapamycin, tacrolimus) (Hopwood 2007). 
Besides Streptomyces and closely related species, other bacterial and fungal species and 
plants produce various polyketides, some of which have less positive effects on human and 
animal	health.	Aflatoxins	and	many	other	mycotoxins,	which	cause	problems	in	food	safety	
and agriculture, are actually polyketides produced by fungal species (Huffman et al. 2010).
Regardless of the identity of the producing organism, all polyketides share a similar 
biosynthetic origin closely related to fatty acid biosynthesis. Polyketide biosynthesis is 
catalyzed by a polyketide synthase (PKS) and involves the decarboxylative condensation 
of small acyl substrates, often malonyl units, bound to an acyl carrier protein (ACP), into 
a longer carbon chain in which every second carbon carries an original keto group of 
the substrate. A fundamental difference between polyketide and fatty acid biosynthesis 
is	the	full	reduction	of	the	β-keto	group	of	each	intermediate	during	fatty	acid	synthesis.	
In bacterial fatty acid synthesis, this is catalyzed by separate enzymes responsible for 
β-ketoreduction,	dehydration	and	enoyl	reduction	steps	(Keller	et al. 2005, White et al. 
2005, Gago et al. 2011). 
Based on the characteristic features of the polyketide synthases, polyketides have been 
classified	into	three	main	categories.	Type	I	synthases	are	large,	multifunctional	megasynthases	
analogous to eukaryotic type I fatty acid synthases, where multiple biosynthetic reactions are 
catalyzed by individual domains within a single polypeptide (Smith & Tsai 2007). While 
bacterial type I megasynthases consist of a separate module for each (methyl)malonyl 
addition, fungal type I systems are limited to a set of domains within one module, which is 
used in a repetitive manner – thus the name “iterative” PKSs (Keller et al. 2005). 
Type II PKSs, on the other hand, are analogous to type II fatty acid synthases found in 
most bacteria, mitochondria and chloroplasts, as their polyketide product is synthesized 
by a number of monofunctional enzymes, which all catalyze different biosynthetic 
reactions one after another (White et al. 2005). A so-called minimal polyketide synthase 
(minPKS) complex consisting of three enzymes catalyzes the iterative condensation 
of	acyl	units	into	a	long	polyketide	chain,	which	is	subsequently	folded	and	modified	
into	 a	 final	 polyketide	 backbone	 by	 dedicated	 enzymes	 like	 cyclases,	 ketoreductases	
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and oxygenases (Schneider 2005, Zhou et al. 2010). Examples of type II or “aromatic” 
polyketides in clinical use are the anthracyclines doxorubicin and aclacinomycin A used 
in the treatment of cancer, and oxytetracycline and tetracenomycin used as antibiotics 
(Fig. 1, Schneider 2005). In addition to anthracyclines, tetracyclines and tetracenomycins, 
important subclasses of type II polyketides include: angucyclines (Kharel & Rohr 
2012); aureolic acids (O’Connor 2004); compounds of the pluramycin group (Sun et 
al. 1993); compounds of the pradimicin type (Xu et al. 2007); pyranonaphthoquinones 
(PNQs, Brimble et al. 1999, Salaski et al. 2009), which are often referred to as 
benzoisochromanequinones (BIQs); and rubromycins (Yunt et al. 2009). Each of these 
compound	classes	is	defined	by	the	presence	of	characteristic	structural	features.	
Figure 1. Structures of type II polyketides in clinical use.
The multidomain type III PKSs found in both bacteria and plants resemble the type 
I enzymes, although they are simpler in their architecture. The homodimeric type III 
synthases are smaller than the type I megasynthases and lack one of the central domains: 
the ACP domain. For this reason, type III synthases catalyze the condensation of diverse 
coenzyme A (CoA)-derivatized substrates rather than the typical ACP-bound small 
substrates of the other polyketide synthases (Gross et al. 2006, Watanabe et al. 2007).
Many polyketides – including medicinally useful ones – are glycosylated, and in several 
cases the sugar moieties have been shown to be important for the biological activities of 
these compounds (Weymouth-Wilson 1997, Kren & Martínková 2001). Glycosylation of 
polyketides typically requires the activation of a sugar by a nucleotidyltransferase, which 
catalyzes the coupling of a sugar-1-phosphate to a nucleoside monophosphate unit of a 
nucleoside triphosphate. The formed nucleoside diphosphate (NDP)-sugar, often an NDP-
d-glucose,	is	then	enzymatically	modified	and	finally	attached	to	the	polyketide	backbone	
by a glycosyltransferase, most often via an O-glycosidic bond (Thibodeaux et al. 2007). 
C-glycosidic bonds – which are hydrolytically more stable – are considered less common, 
although there are several examples of C-glycosylated polyketides (Hultin 2005).
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2.2 the structures and biological activities of the PnQ polyketides 
produced by Streptomyces species  
A common structural nominator of compounds belonging to the PNQ subclass of type 
II polyketides is a fused, relatively planar 3-ring structure composed of a pyran, a 
quinone and a benzene ring (Brimble et al. 1999, Salaski et al. 2009). The presence of 
the quinone ring explains the pH-indicator property of pyranonaphthoquinones; the red 
and yellow compounds turn blue or purple in alkaline conditions (Takano et al. 1976). 
The p-quinone is most often found as the central ring, like in the model compound 
actinorhodin, but in alnumycin A it has an atypical position as a lateral ring. The aglycone 
structures also differ in the pattern of oxygenation, as only actinorhodin, alnumycin A 
and granaticin are oxygenated at C-8 (reversed biosynthetic numbering: the carbons of 
the unfolded polyketide chain are numbered starting from the terminal carboxylic acid 
carbon). The terminal carboxylic acid, which is not present in alnumycin A, is often 
found in a cyclized g-lactone form. Curiously, while none of the PNQ polyketides are 
directly O-glycosylated, both granaticin and medermycin are C-glycosylated (Fig. 2).
Figure 2. Structures of representative PNQ polyketides and the PNQ-like natural product 
α-naphthocyclinone.	Reversed	biosynthetic	numbering	(actinorhodin	and	nanaomycins),	carbon	
numbering for alnumycin A and nomenclature for lactone ring carbons (frenolicin B) are shown.
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The model compound actinorhodin produced by Streptomyces coelicolor A3(2) has an 
atypical dimeric structure, where two identical units are coupled via a C10–C10 bond 
(Fig. 2). Actinorhodin was reported to only have low antibiotic activity against Gram-
positive species, which is possibly compensated by the relatively high production levels 
of actinorhodin observed for S. coelicolor A3(2) (Wright & Hopwood 1976). 
Alnumycin A was isolated in 1998 from both Streptomyces sp. DSM 11575 (Bieber 
et al.. 1998) and Streptomyces griseorubiginosus strain Mer-K1115, under the name 
K1115 B1 (Naruse et al. 1998). The non-glycosylated alnumycin A is an exceptional 
member of the PNQ class in having a unique sugar-like 4’-hydroxy-5’-hydroxymethyl-
2’,7’-dioxane moiety attached via a C–C bond to the polyketide backbone (Bieber et al. 
1998, Naruse et al. 1998, Fig. 2). Very recently, stereochemical analysis of alnumycin 
A isolated from cultures of Streptomyces sp. CM020 revealed exceptionally complex 
stereochemistry for the compound. Alnumycin A was found to be produced as three 
pairs of stereoisomers, one of which consisted of previously reported compounds with 
a (1R,	1ʹRS,	4ʹRS,	5ʹSR)	configuration	(Tatsuta	et al. 2011, Tähtinen et al. 2012). The 
plausible	configurations	of	the	two	novel	pairs	of	stereoisomers	were	(1R,	1ʹRS,	4ʹSR, 
5ʹSR) and (1R,	1ʹRS,	4ʹSR,	5ʹRS) (Oja et al. 2012). The biological activities reported for 
alnumycin A include antibacterial activity against Gram-positive species and cytostatic 
activity against human leukemia cells, as well as inhibitory activity against gyrase and 
topoisomerases 1 and 2 (Bieber et al. 1998, Björn & Jörg 1998).
Frenolicin, originally isolated from cultures of Streptomyces fradiae, can be easily 
converted to deoxyfrenolicin by chemical reduction of the epoxide (Ellestad et al.1968). 
Chemical oxidation of deoxyfrenolicin, on the other hand, leads to the formation of its 
g-lactone derivative frenolicin B (Fig. 2, Fitzgerald et al. 2011a). Both deoxyfrenolicin 
and frenolicin B were isolated from Streptomyces roseofulvus strain AM-3867, and they 
showed promising antimicrobial activity against fungi and mycoplasma (Iwai et al. 1978). 
Other reported activities of frenolicin B include strong inhibition of platelet aggregation, 
compared to deoxyfrenolicin and other selected naphthoquinones (Nakagawa et al. 
1987), and anticoccidial activity against the parasite Eimeria tenella in chickens. In the 
latter case, the presence of the g-lactone ring was suggested to be important for the 
high antiparasite activity (Omura et al. 1985). Frenolicin B was also found to possess 
moderate in vitro activity against human malarial pathogen Plasmodium falciparum and 
to be well tolerated, with no acute toxicity in rats (Fitzgerald et al. 2011a). Recently, both 
deoxyfrenolicin and frenolicin B were recognized as promising anticancer compounds, 
possibly owing to their selective kinase inhibitory activity against a serine-threonine 
kinase AKT, which is known to be constitutively activated in a wide variety of human 
tumor types. A similar inhibitory effect was observed for kalafungin and medermycin, 
and the PNQ compounds were proposed to act via an S-alkylation mechanism of a 
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cysteine residue, involving the reduction of the quinone ring to a hydroquinone and 
subsequent opening of the g-lactone ring (Toral-Barza et al. 2007, Salaski et al. 2009). 
The granaticin producing strain Streptomyces violaceoruber Tü22 produces several 
related granaticins, which contain a 2,6-dideoxy-d-glucose moiety connected to the 
aglycone in a highly unusual manner via two C–C bonds, thus forming an additional, 
fourth fused ring.  Both granaticin B and the non-lactone form dihydrogranaticin B are 
even	O-glycosylated,	but	only	indirectly	at	one	of	the	hydroxyl	groups	of	the	first	sugar	
moiety (Fig. 2, Ichinose et al. 1998). The reported biological activities of granaticin 
include antibiotic activity against Gram-positive bacteria (Hultin 2005), cytotoxicity 
against human oral epidermoid carcinoma (KB) cells (Heinstein 1982) and an inhibitory 
effect on pyruvate decarboxylase (Gibson-Clay et al. 1982). Additionally, also granaticin 
B was found to be active against Gram-positive bacteria, and to inhibit the growth of 
transplanted tumors in rodent models (Hultin 2005).
Griseusins A and B, synthesized by a type II polyketide synthase of Streptomyces griseus 
K-63 (Yu et al. 1994), only differ in the former being a g-lactone and the latter a non-
lactone form. Both were reported to have potent antibacterial activity against Gram-
positive species (Tsuji et al. 1976). 
Contrary to the weak antibacterial activity observed for actinorhodin, its biosynthetic 
intermediate	 kalafungin	 (Fig.	 2),	 first	 isolated	 from	 Streptomyces tanashiensis strain 
Kala UC-5063 (Cole et al. 1987), was shown to have relatively wide-spectrum 
antibacterial activity, as well as potent activity against a variety of pathogenic fungi, 
yeasts and protozoa (Johnson & Dietz 1968). Interestingly, the antibacterial properties of 
kalafungin were reported to be very similar to its enantiomer nanaomycin D, indicating 
that	in	this	case	the	stereochemistry	of	the	compound	would	not	significantly	affect	its	
biological activity (Tatsuta et al. 1991).   
Medermycin, also referred to as natural lactoquinomycin (Tatsuta et al. 1990, Hultin 
2005), was isolated from cultures of S. tanashiensis K73 (Takano et al. 1976). The 
compound was found to be C-glycosylated with a glucose-derived angolosamine 
moiety (Ichnose et al. 2003). Medermycin was reported to show promising antibacterial 
activity against Gram-positive species, including resistant Staphylococcus aureus 
strains (Takano et al. 1976, Tatsuta et al. 1991), inhibition of platelet aggregation 
(Nakagawa et al. 1987), activity against Ehrlich carcinoma in mice, and cytotoxicity 
against leukemia and lymphoblastoma cell lines (Tanaka et al. 1985, Hultin 2005). 
Analogously to kalafungin and its enantiomer, the natural (+)-medermycin was found 
to exhibit similar antibacterial activity as its unnatural enantiomer, suggesting that the 
stereochemistry of the lactone ring or the C-glycoside is not important for its antibiotic 
activity (Tatsuta et al. 1991). 
 Literature Review 
15
Nanaomycins A, B, C, D and E were isolated from cultures of Streptomyces rosa var. 
notoensis,	and	their	polyketide	origin	was	verified	by	feeding	experiments	using	labeled	
1-13C-acetate (Tanaka et al. 1975a, Kasai et al. 1979). Rather curiously, it was found that 
the nanaomycin producing strain also produces frenolicin and similarly, the frenolicin 
B producing S. roseofulvus AM-3867 produces nanaomycin A (Tsuzuki et al. 1986). 
The structure of nanaomycin B differs from other nanaomycins in being hydroxylated 
at position 14, thus lacking the typical double bond between carbons 5 and 14 (Fig. 
2, Tanaka et al. 1975b), which is also missing from a frenolicin-like epoxy derivative 
of  nanaomycin A, nanaomycin E (Kasai et al. 1979). The g-lactone form nanaomycin 
D is likely to be a biosynthetic intermediate, as it could be converted to nanaomycin 
A in vitro through either enzymatic or chemical reduction of the quinone, which was 
proposed to lead to lactone ring opening via intramolecular electron transfer from the 
hydroquinone product (Tanaka et al. 1982). The comparison of biological activities 
of nanaomycins A–C to activities of several derivatives indicated that presence of the 
phenolic hydroxyl group is important for the observed antimicrobial activity against 
Gram-positive bacteria, fungi and mycoplasma (Tanaka et al. 1975c). Recently, 
nanaomycin A was reported to selectively inhibit human DNA methyltransferase 3B 
leading to the reactivation of silenced tumor suppressor genes in human cancer cells 
(Kuck et al. 2010).  
A	dimeric	PNQ-like	 compound	α-naphthocyclinone	 lacking	 a	 complete	 quinone	 ring	
was isolated from cultures of Streptomyces arenae DSM 40737 (Zeeck & Mardin 1974), 
and	 the	 polyketide	 origin	 of	 the	 compound	was	 confirmed	 by	 gene	 inactivation	 and	
heterologous expression experiments (Brünker et al. 1999). Different oxygenation and 
cyclization patterns were observed for the two units, which are fused via two C–C bonds 
(Zeeck	&	Mardin	1974).	Intriguingly,	α-naphthocyclinone	is	another	example	of	a	PNQ-
type	aglycone	modified	via	C–C	bond	formation,	and	in	all	cases	the	position	of	one	C–C	
bond is analogous to the position C-10 of actinorhodin (Fig. 2).  
2.3 PnQ biosynthetic gene clusters
Type II polyketide biosynthetic genes tend to reside clustered in Streptomyces genomes, 
which enables the analysis and expression of complete biosynthetic clusters cloned 
as single, large DNA fragments. In addition to the alnumycin cluster characterized 
in this study, complete biosynthetic gene clusters have been cloned, sequenced and 
heterologously expressed for three PNQ polyketides: the actinorhodin gene cluster from 
S. coelicolor A3(2) (Malpartida & Hopwood 1984), the granaticin gene cluster from 
S. violaceoruber Tü22 (Ichinose et al. 1998) and the medermycin gene cluster from S. 
sp. AM-7161 (Ichinose et al. 2003). Sequence analysis of the gene clusters revealed 
22, 37 and 34 ORFs (open reading frames) likely to be involved in the biosynthesis 
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of actinorhodin, granaticin and medermycin, respectively. Also the frenolicin, griseusin 
and naphthocyclinone biosynthetic gene clusters from S. roseofulvus, S. griseus and S. 
arenae have been partially cloned and sequenced (Bibb et al. 1994, Yu et al. 1994, 
Brünker et al. 1999).   
Comparative sequence analysis of the actinorhodin, granaticin and medermycin gene 
clusters revealed that a high degree of sequence identity was generally found for 
PKS-stage enzymes involved in the synthesis of the polyketide chain and the closely 
associated	first	and	second	ring	cyclization	steps.	An	unexpected	finding	was	the	location	
of the medermycin ACP gene, which was not discovered immediately downstream of 
the minPKS ketosynthase genes, but instead 20 kbp upstream of them, together with 
med-orf24 deduced to code for a holo-ACP synthase. Another curious feature of the 
medermycin cluster was the presence of an ORF (med-orf22) deduced to code for an 
acyl-CoA carboxyl transferase (Ichinose et al. 2003), but the possible role of the gene 
product in malonyl-CoA formation has not been investigated. 
2.4 the early biosynthetic steps of PnQ polyketides
2.4.1 the formation of the polyketide chain by minimal PKS enzymes 
The mechanism of polyketide chain formation is fairly well understood, as PNQ 
ketosynthase (KS) enzymes are homologous to both fatty acid synthases and other 
polyketide	synthases.	Together	with	an	ACP,	ketosynthase	α	(KSα, KS) and ketosynthase 
β	(KSβ, chain length factor, CLF) form the minPKS complex and catalyze the condensation 
of malonyl units in a decarboxylative manner into a long polyketide chain (Carreras & 
Khosla 1998).
Polyketide	biosynthesis	 is	 typically	 initiated	by	 the	decarboxylation	of	 the	first	ACP-
bound malonyl unit (Fig. 3a) catalyzed by the KS, followed by the transfer of the 
formed acetyl unit to a conserved cysteine residue of the KS. The decarboxylation of the 
second malonyl-ACP generates a negatively charged acetyl intermediate, which acts as 
a	nucleophile	and	attacks	the	carbonyl	carbon	of	the	first	KS-bound	acetyl	unit,	forming	
a four-carbon long diketide attached to the ACP. The diketide is then transferred to the 
conserved cysteine residue of the KS, and the next malonyl-ACP is decarboxylated (Fig. 
3b). Similar Claisen condensations between the growing polyketide chain and malonyl-
ACP units are repeated until a polyketide product of correct length is formed (Dreier & 
Khosla 2000, Keatinge-Clay et al. 2004). 
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Figure 3. a) The chemical structure of a malonylated phosphopantetheine arm of a holo-ACP. b) 
A	simplified	model	for	the	decarboxylative	condensation	reaction	catalyzed	by	the	minPKS.	One	
two-carbon extension unit is circled with a dashed gray line. 
Malonyl building blocks for polyketide synthesis are activated by the transfer from 
malonyl-CoA to an ACP, which is possibly catalyzed by a malonyl–CoA:ACP 
transacylase (MAT) enzyme shared with fatty acid metabolism (Carreras & Khosla 1998, 
Gago et al. 2011). MAT is able to catalyze the covalent attachment of each malonyl 
unit as a thioester to a phosphopantetheine arm of a holo-ACP (Fig. 3a), but even self-
malonylation of type II holo-ACPs in vitro has been reported (Hitchman et al. 1998). 
Thus, it has been suggested that there might be no absolute requirement for a MAT in 
polyketide biosynthesis (Matharu et al. 1998, Arthur et al. 2005). 
Only	holo-ACPs	can	be	malonylated,	and	the	post-translational	modification	of	an	apo-
ACP is catalyzed by a holo-ACP synthase (“phosphopantetheinyl transferase”). The 
holo-ACP synthase catalyzes the transfer of a phosphopantetheine chain (Fig. 3a) from 
CoA to a conserved serine residue of an apo-ACP. Two of the known PNQ gene clusters 
harbor putative genes for holo-ACP synthases (med-orf24 and gra-orf32, Ichinose et al. 
2003),	although	the	covalent	modification	of	many	type	II	apo-ACPs	might	be	catalyzed	
by an enzyme shared with fatty acid biosynthesis. In the actinorhodin producing S. 
coelicolor one of the three deduced holo-ACP synthases, AcpS, was suggested to be 
essential for fatty acid biosynthesis (Lu et al. 2008), and shown in vitro to catalyze 
phosphopantetheinyl transfer to both fatty acid synthase ACP and actinorhodin ACP 
(Cox et al. 2002). Recently, AcpS was reported to bind both apo-ACPs with very similar 
dissociation constants (Dall’Aglio et al. 2011). 
It has been proposed that the formed polyketide chain would remain attached to the 
ACP (Khosla 2009), but the exact timing of the thioester hydrolysis is not known. The 
solution structure of the actinorhodin ACP revealed that the small four-helix bundle 
protein	exhibits	more	conformational	flexibility	 than	 the	structurally	closely	 related	
Escherichia coli ACP involved in fatty acid biosynthesis (Evans et al. 2009), and the 
deduced interaction of actinorhodin ACP with the C-9 ketoreductase ActIII has been 
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modeled	 (Hadfield	et al. 2004). However, currently there is no direct experimental 
evidence for interaction of a type II polyketide ACP with any of the “downstream” 
enzymes. 
Due to high reactivity and possibility of spontaneous, incorrect cyclizations of the 
polyketide	chain,	the	first	cyclization	events	have	proved	challenging	to	dissect	from	the	
minPKS catalyzed reactions. The in vitro production of polyketides with one correctly 
cyclized ring, using only minPKS enzymes, a MAT and malonyl-CoA as a substrate, has 
led	to	the	proposal	that	the	minPKS	complex	might	partially	control	the	first	cyclization	
of the formed polyketide chain (Carreras & Khosla 1998). 
The hypothesis that the KS–CLF dimer not only determines the chain length, but also 
promotes	correct	first	ring	cyclization,	was	supported	by	the	high-resolution	structure	of	
the actinorhodin KS–CLF dimer (ActI-Orf1–ActI-Orf2) with bound intermediates. The 
homologous KSα and CLF were found to share the expected, conserved thiolase fold, 
and	an	active	site	was	verified	to	be	created	by	the	relatively	large	dimer	interface.	The	
crystal structure revealed that catalytically important residues are either not conserved 
or not positioned correctly in the CLF, and highlighted the central catalytic role of KSα. 
The dimer interface was proposed to determine the length of the active site tunnel, and 
it	was	suggested	that	the	growing	polyketide	chain	is	forced	to	bend	in	order	to	fit	inside	
the tunnel (Keatinge-Clay et al. 2004). 
2.4.2 Starter unit synthesis
Actinorhodin minPKS and most other PNQ minPKSs catalyze the decarboxylative 
condensation of 8 malonyl-ACP units into 16-carbon long polyketide chains, 
whereas alnumycin and frenolicin are formed from 18-carbon long polyketide 
chains. Curiously, the same minPKS that is responsible for the production of 
the 18-carbon long frenolicin can apparently also synthesize the 16-carbon long 
polyketide nanaomycin (Bibb et al. 1994, McDaniel et al. 1994). The difference 
in chain lengths originates from the use of an alternative starter unit in place of an 
acetyl unit of a malonyl-ACP, and the frenolicin gene cluster harbors genes coding 
for	 an	 additional	 ketoacyl	 synthase	 (FrnI),	 acyl	 transferase	 (FrnK)	 and	 a	 specific	
ACP (FrnJ) involved in the priming of the polyketide chain synthesis with a longer 
starter unit (Tang et al. 2003). 
The homodimeric starter unit ketoacyl synthase FrnI is homologous to the bacterial 
β-ketoacyl-ACP	 synthase	 III	 (KSIII,	 FabH),	 which	 is	 known	 to	 catalyze	 the	
decarboxylative condensation of malonyl-ACP with a priming acyl-CoA at the 
initiation stage of fatty acid synthesis (White et al. 2005). It has been proposed that 
frenolicin biosynthesis might be initiated in a similar manner, by the decarboxylative 
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condensation	 of	 malonyl-ACP	 and	 acetyl-CoA.	 Subsequent	 reduction	 of	 the	 β-keto	
group of the formed diketide, followed by dehydration and reduction steps catalyzed 
by	 unidentified	 enzymes	 possibly	 shared	 with	 fatty	 acid	 biosynthesis,	 would	 yield	
a butyryl-ACP starter unit. The hypothesis was supported by in vitro analysis of the 
priming KS and ACP enzymes; FrnI accepted malonyl-FrnJ and labeled acetyl-CoA 
as substrates, while malonylated minPKS-ACPs were poor substrates for starter unit 
synthesis by FrnI. It was concluded that the starter unit and minPKS ACPs seem to be 
specific	 for	 the	 respective	ketosynthases,	although	several	 studies	have	 indicated	 that	
the minPKS ketosynthases are able to recognize ACPs from different type II polyketide 
pathways (McDaniel et al. 1993, Tang et al. 2003). Recently, frenolicin starter unit and 
minPKS genes were coexpressed in a Streptomyces host with several genes encoding 
actinorhodin downstream enzymes (ActIII, ActIV, ActVII, ActVI-Orf1, ActVI-Orf2 and 
ActVB), which resulted in the successful production of low levels of deoxyfrenolicin, 
with butyryl-primed shunt products as the main relevant secondary metabolite products 
(Fitzgerald et al. 2011b). 
A similar set of three proteins homologous to frenolicin starter unit enzymes was shown 
to catalyze starter unit formation in the biosynthesis of a type II polyketide R1128 (Marti 
et al. 2000, Tang et al. 2004). The high-resolution crystal structure of the starter unit 
ketoacyl-ACP synthase ZhuH from Streptomyces sp. R1128 was obtained in complex 
with one of the alternative substrates, acetyl-CoA, and the overall fold of ZhuH was 
found to be similar to that of FabH from E. coli and other priming ketosynthases 
from fatty acid biosynthetic pathways (Pan et al. 2002). Intriguingly, the starter unit 
acyl transferase ZhuC from the R1128 pathway was proposed to act as a thioesterase, 
catalyzing the hydrolysis of incorrect acyl groups attached to the starter unit ACP, thereby 
enabling	more	efficient	priming	of	the	polyketide	synthesis	with	longer	starter	units,	like	
hexanoyl-ACP (Tang et al. 2004). 
2.4.3	 The	first	and	the	second	ring	cyclizations	
On	PNQ	pathways,	the	first	two	ring	cyclizations	are	so	intimately	linked	to	ketoreduction	
at position C-9 that the exact order of these events has proved challenging to determine. 
Functional studies of the actinorhodin C-9 ketoreductase ActIII revealed that in vitro 
co-incubation of actinorhodin minPKS enzymes with the ketoreductase increased the 
yield	 of	 a	 shunt	 product,	mutactin,	with	 a	 correctly	 cyclized,	 reduced	first	 ring	 (Fig.	
4). Curiously, another shunt product SEK4, with a correctly cyclized but unreduced 
first	ring	(Fig.	4),	is	produced	even	without	the	addition	of	the	ketoreductase	(Hadfield	
et al.	2004).	This	finding,	 together	with	 the	observed	high	regiospecificity	of	 the	C-9	
ketoreductases, has supported the hypothesis that already the minPKS might promote 
the	first	ring	cyclization	(Korman	et al. 2004).
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Figure 4. Structures of selected shunt products from the actinorhodin biosynthetic pathway. R 
= COOH in DMAC (3,8-dihydroxy-1-methylanthraquinone-2-carboxylic acid) and R = H in 
aloesaponarin II. Reversed biosynthetic numbering is shown.
The	presence	of	a	gene	coding	 for	a	dedicated	first	 ring	cyclase/dehydratase/aromatase	
in many aromatic polyketide gene clusters, including the PNQ gene clusters, suggests 
that	a	specific	cyclase	would	be	responsible	for	the	aldol	condensation	between	C-7	and	
C-12 (reversed biosynthetic numbering, Zhou et al. 2010). Recent structural and in vitro 
activity studies of a cyclase ZhuI involved in R1128 biosynthesis, homologous to PNQ 
cyclases,	provided	evidence	on	the	dual	role	of	ZhuI	as	a	regiospecific	first	ring	cyclase	
and a dehydratase. Initial deprotonation at position 12, which is plausible due to the weak 
acidity of the hydrogen next to the two carbonyl groups and resonance stabilization of the 
formed enolate ion, was proposed to lead to a nucleophilic attack on C-7 and subsequent 
protonation of the C-7 keto group. The resulting hydroxyl group was suggested to be 
removed via dehydration involving an enzyme catalyzed second deprotonation at position 
12 and a protonation of the newly formed C-7 hydroxyl group (Fig. 5, Ames et al. 2011). 
Figure 5. A model for aldol condensation and dehydration steps involved in the formation of 
the	first	aromatic	ring.	The	C-9	keto	group	shown	may	even	be	reduced	prior	 to	 the	first	 ring	
formation. KR = C-9 ketoreductase, CYC = cyclase, R=CH2CH2CH3 on the frenolicin pathway, 
and R=CH3 on actinorhodin, granaticin and medermycin pathways. 
On	the	actinorhodin	pathway,	ActIV	was	identified	as	a	probable	second	ring	cyclase	
responsible for another aldol condensation step. Early studies on actinorhodin 
biosynthesis revealed that the expression of a gene cassette coding for the actinorhodin 
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minimal PKS, ketoreductase ActIII, cyclase/dehydrase ActVII and second cyclase 
ActIV introduced into S. coelicolor	 CH999	 was	 sufficient	 for	 the	 production	 of	 the	
three-ring naphthoquinone compounds DMAC (3,8-dihydroxy-1-methylanthraquinone-
2-carboxylic acid) and its decarboxylated derivative aloesaponarin II (Fig. 4), both with 
the	first	 two	 rings	correctly	cyclized	 (McDaniel	et al. 1993). The presence of a gene 
coding for a second ring cyclase homologous to ActIV in all known PNQ gene clusters, 
including the partially isolated frenolicin cluster, suggests that a related cyclase of a 
metallo-beta-lactamase superfamily would catalyze the second ring formation on other 
PNQ pathways, as well.
PNQ polyketide ketoreductases and other aromatic polyketide C-9 ketoreductases are 
homologous NAD(P)H -dependent enzymes of the short chain dehydrogenase/reductase 
(SDR) family, deduced to fold into a conserved Rossmann fold. Recent structural and 
kinetic studies of the C-9 ketoreductase ActIII showed that the enzyme prefers bicyclic 
substrate analogs and is inhibited by a tricyclic compound emodin, which was bound into 
the active site upon cocrystallization with NADP(H) (Korman et al. 2008). The results 
support	the	hypothesis	that	C-9	ketoreduction	might	occur	after	the	first	ring	cyclization,	
and that the natural substrate might even be a bicyclic pathway intermediate, but the 
molecular	basis	for	the	regiospecificity	of	the	ketoreduction	is	still	not	understood	very	
well (Korman et al. 2008, Javidpour et al. 2011). A granaticin biosynthetic enzyme of the 
SDR	family,	Gra-Orf5,	was	identified	as	a	C-9	ketoreductase	able	to	substitute	for	ActIII	
in an in vivo experiment (Taguchi et al. 2001). 
2.5 the tailoring of the polyketide backbone on PnQ pathways
2.5.1 Pyran ring formation
Third	ring	formation	can	be	considered	the	first	post-PKS/tailoring	step	(Itoh	et al. 2007), 
and it has been possible to study the biosynthetic step without the presence of minPKS 
enzymes. On several PNQ biosynthetic pathways, third ring formation has been suggested 
to involve an enzyme catalyzed ketoreduction step followed by hemiketal formation, 
dehydration and reduction steps, resulting in a pyran ring. On the actinorhodin pathway, 
ActVI-Orf1 of the 3-hydroxyacyl-CoA dehydrogenase (3HAD) protein family catalyzes 
the C-3 ketoreduction leading to the 3S-configuration	of	the	pathway	intermediate	DNPA	
(4-dihydro-9-hydroxy-1-methyl-10-oxo-3-H-naphtho[2,3-c]pyran-3-acetic acid, Fig. 6, 
Ichinose et al. 1999, Taguchi et al. 2001, Taguchi et al. 2004). Functional studies of 
ActVI-Orf1 (“RED1”) suggested that the enzyme would prefer non-ACP bound bicyclic 
substrates (Itoh et al.	2007).	The	stereospecificity	of	a	ketoreductase	Med-Orf12	from	
the medermycin pathway was found to be similar to its homologue ActVI-Orf1, as the 
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heterologous expression of med-orf12 together with early actinorhodin biosynthetic 
genes resulted in the successful production of S-DNPA (Li et al. 2005). 
On the granaticin pathway, the expression of gra-orf6 in combination with early 
biosynthetic genes suggested that it was essential for pyran ring formation. Gra-Orf6 of 
the	SDR	protein	family	was	thus	identified	as	a	probable	C-3	ketoreductase	responsible	
for the formation of the 3R-configuration in R-DNPA (Taguchi et al. 2001). 
The possible C-3 ketoreduction event on the frenolicin/nanaomycin biosynthetic 
pathway is intriguing, but not very well understood, as the enzymes responsible for 
pyran	ring	formation	are	yet	to	be	identified.	The	opposite	stereochemistry	of	frenolicins	




responsible for completing the pyran ring synthesis and the observed (3S, 15R) 
configuration	 (Fig.	 6),	 as	 inactivation	 of	 actVI-orf2 resulted in the production of 
S-DNPA in place of actinorhodin (Fernández-Moreno et al. 1994). Based on amino acid 
(aa) sequence similarity, ActVI-Orf2 belongs to the medium-chain dehydrogenases/
reductase (MDR) family of proteins, which contain a conserved Rossmann fold domain 
for the binding of NAD(P)H. The biosynthetic role of the enoyl reductase ActVI-Orf2 
was	confirmed	by	recent	 in vivo experiments, as the expression of early actinorhodin 
biosynthetic genes in S. coelicolor CH999 only resulted in the successful production 
of dihydrokalafungin (Fig. 6) in the presence of actVI-orf2, while actVI-orf1 was again 
found to be essential for the production of S-DNPA (Fig. 6, Fitzgerald et al. 2011b).  
2.5.2 tailoring stage monooxygenases 
Pyran ring formation is followed by either one or two oxygenation events to complete 
the biosynthesis of the three-ring chromophore. The introduction of an oxygen atom 
into position C-6 of the central ring results in a p-quinone structure. Two non-related 
monooxygenases – ActVA-Orf6 and the two-component ActVA-Orf5–ActVB – have 
been shown to catalyze the same C-6 oxygenation in actinorhodin biosynthesis (Fig. 6, 
Kendrew et al. 1997, Okamoto et al. 2009). ActVA-Orf6 belongs to a family of cofactorless 
monooxygenases, and it utilizes a conserved ferredoxin fold in a dimeric fashion. The 
high-resolution crystal structures of the monooxygenase in complex with substrate and 
product analogues led to a mechanistic proposal involving the activation of molecular 
oxygen by the substrate 6-deoxydihydrokalafungin. An initial deprotonation of the C-13 
hydroxyl group of a tautomer of the substrate was proposed to lead to the stabilization 
of a C-6 carbanion resonance form (Fig. 6), which could react with molecular oxygen 
 Literature Review 
23
to	form	a	C-6	peroxy	intermediate	and	finally	a	C-6	keto	group	through	protonation	and	
dehydration steps (Sciara et al. 2003). 
The	ActVA-Orf5–ActVB	system,	on	the	other	hand,	is	a	two-component	flavin-dependent	
monooxygenase, with the components belonging to acyl-CoA dehydrogenase (ACAD) and 
flavin	reductase	(FlaRed)	protein	families,	respectively	(Valton	et al. 2006, Okamoto et al. 
2009). The role of ActVA-Orf5–ActVB in C-8 hydroxylation, but not C-6 oxygenation, 
was demonstrated earlier by both in vivo and in vitro studies. The inactivation of the gene 
actVB	coding	for	the	flavin	reductase	component	was	found	to	result	in	the	accumulation	of	
the pathway intermediate kalafungin (Fig. 2), which is a g-lactone compound oxygenated 
at position C-6 (Cole et al. 1987). Furthermore, the two-component monooxygenase 
was reported to catalyze the C-8 hydroxylation of a reduced hydroquinone form of 
dihydrokalafungin in vitro (Fig. 6, Valton et al. 2006, 2008). 
Figure 6. A	 simplified	 representation	 of	 the	 tailoring	 steps	 on	 the	 actinorhodin	 biosynthetic	
pathway. 
The recently reported C-6 monooxygenase activity of ActVA-Orf5–ActVB was 
likewise	confirmed	both	in vitro by the enzymatic oxygenation of a substrate analogue 
emodinanthrone and by in vivo mutagenesis studies. Co-deletion of the overlapping 
actVA-orf5 and actVA-orf6 abolished actinorhodin formation and resulted in the 
accumulation of actinoperylone with neither of the two positions oxygenated (Fig. 
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4), while the deletion of actVA-orf6	 did	 not	 seem	 to	 have	 any	 significant	 effect	 on	
actinorhodin production. Furthermore, the double mutant strain was complemented by 
the expression of actVA-orf5, but not actVA-orf6, indicating that the two-component 
monooxygenase	was	sufficient	for	both	oxygenation	events	(Okamoto	et al. 2009). 
An additional oxygenation activity was recently reported for the two-component ActVA-
Orf5–ActVB system (Taguchi et al. 2011). In accordance with earlier reports related to 
in vitro enzymatic activity of the system (Valton et al. 2006), C-8 oxygenation could not 
be observed, as the substrate dihydrokalafungin was not reduced. Instead, epoxyquinone 
products resembling the structure of frenolicin (Fig. 2) were obtained. The observed 
epoxykalafungin products were g-lactone compounds, which could result from the 
oxidative lactonization of dihydrokalafungin (Taguchi et al. 2011). An analogous 
chemical oxidation of deoxyfrenolicin to a g-lactone derivative was reported recently 
(Fitzgerald et al. 2011a). 
Interestingly, both granaticin and medermycin gene clusters encode proteins homologous 
to the two-component ActVA-Orf5–ActVB system, but they lack a gene coding for a 
cofactorless monooxygenase homologous to ActVA-Orf6, although medermycin is not 
oxygenated at position C-8. Therefore, it is plausible that the two-component system 
would catalyze C-6 oxygenation on actinorhodin, granaticin and medermycin pathways 
(Ichinose et al. 2003).   
Very recently, the actinorhodin monomer – 8-hydroxy-dihydrokalafungin  – was isolated 
from an actVA-orf4 deletion mutant strain. The gene product ActVA-Orf4 of a superfamily 
of Rossmann-fold NAD(P)-binding proteins was thus suggested to have a role in the 
dimerization of actinorhodin. However, it is not clear whether the dimerization occurs 
prior to or after the C-8 oxygenation (Taguchi et al. 2012). 
2.6 the glycosylation of PnQ polyketides
Two of the PNQ polyketides discussed here are glycosylated; medermycin is decorated 
with an angolosamine moiety attached via a C–C bond to position C-10, while all 
granaticins	 contain	 a	 4ʹ-keto-2ʹ,6ʹ-dideoxyhexose	 sugar,	 4ʹ-keto- d-olivose, attached 
in a highly unusual manner via two C–C bonds to C-9 and C-10. In granaticin B and 
dihydrogranaticin	B	there	is	even	a	2ʹ,3ʹ,6ʹ-trideoxyhexose,	L-rhodinose,	attached	to	the	
first	sugar	via	a	conventional	O-glycosidic	bond	(Fig.	2,	Ichinose	et al. 1998).  
Cloning, sequencing and heterologous expression of the complete medermycin and 
granaticin	 gene	 clusters	 has	 enabled	 the	 identification	 of	 the	 probable	 deoxysugar	
biosynthetic genes (Ichinose et al. 1998, 2003). Sequence analysis of the medermycin 
gene cluster revealed six putative genes responsible for the biosynthesis of the deoxysugar 
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angolosamine, all of which were found next to each other and transcribed in the same 
direction. Many of the genes were even found to be overlapping in a manner suggestive 
of translational coupling (Ichinose et al. 2003). Sequence analysis of the granaticin 
cluster revealed eight gene products deduced to function in deoxysugar biosynthesis, 
and the genes were again found next to each other (Ichinose et al. 1998).
The	first	three	biosynthetic	steps	are	believed	to	be	similar	and	catalyzed	by	homologous	
enzymes in both medermycin and granaticin deoxysugar biosynthesis. The initial 
formation of the activated sugar, NDP-glucose, is probably catalyzed by Med-18/
Gra-Orf16 (GraD), homologous to dTDP-glucose synthases including StrD from the 
biosynthetic pathway of the aminoglycoside antibiotic streptomycin (Bechthold et al. 
1995).	The	next	biosynthetic	step	is	the	formation	of	NDP-4ʹ-keto-6ʹ-deoxyglucose	from	
NDP-glucose catalyzed by a dehydratase Med-17/Gra-Orf17 (GraE), again homologous 
to a streptomycin biosynthetic enzyme from S. griseus, among others (Bechthold et 
al.	 1995),	 followed	 by	 2ʹ-deoxygenation	 catalyzed	 by	 Med-16/Gra-Orf27.	 On	 the	
medermycin pathway, the remaining angolosamine biosynthetic steps were suggested to 
be catalyzed by an aminotransferase homologue Med-20, a 4-ketoreductase Med-14 and 
an N-methyltransferase Med-15 (Fig. 7, Ichinose et al. 2003).
On the granaticin biosynthetic pathway, Gra-Orf26 was suggested to catalyze 
3ʹ-ketoreduction	following	the	2ʹ-deoxygenation	step	catalyzed	by	Gra-Orf27.	In vitro 
enzymatic	 conversion	 of	 dTDP-4ʹ-keto-6ʹ-deoxyglucose	 by	 Gra-Orf27	 into	 either	 an	
unstable	 product	 or,	 in	 the	 presence	 of	 Gra-Orf26,	 a	 reduced	 2ʹ,6ʹ-dideoxy	 product	
provided experimental evidence for the activities of these enzymes. Furthermore, 
it	 was	 proposed	 that	 the	 reduced	 2ʹ-deoxygenation	 product,	 dTDP-4ʹ-keto-2ʹ,6¢-
dideoxyglucose, would be transferred to the granaticin aglycone, making it the last 
common	pathway	intermediate	in	the	biosynthesis	of	both	the	first	and	the	second	sugar	
of the granaticins (Fig. 7, Draeger et al. 1999). 
Figure 7. A	 simplified	 model	 for	 deoxysugar	 biosynthesis	 on	 medermycin	 and	 granaticin	
pathways. 
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Gene inactivation experiments have provided experimental evidence on the biosynthetic 
steps leading to the formation of the second sugar L-rhodinose in granaticin B, as 
individual inactivation of any of the four genes gra-orf22–25 resulted in complete 
or close to complete abolishment of (dihydro)granaticin B production but did not 
affect the production of granaticin. Based on aa sequence similarities, Gra-Orf23 was 
proposed	to	catalyze	3ʹ-deoxygenation,	Gra-Orf25	3ʹ(5ʹ)-epimerization,	and	Gra-Orf22	
4ʹ-ketoreduction	(Tornus	&	Floss	2001).	
Only one ORF coding for a putative glycosyltransferase  – gra-orf14 – was discovered 
in the granaticin gene cluster. As expected, the gene product was deduced to belong to 
the glycosyltransferase B-family, together with most prokaryotic glycosyltransferases 
involved in secondary metabolite glycosylation (Thibodeaux et al. 2007), and to be 
homologous to the medermycin glycosyltransferase Med-8 (46% aa level identity). 
Gra-Orf14 and Med-8 are even homologous to the known C–C bond forming 
glycosyltransferase UrdGT2 from Streptomyces fradiae, which catalyzes the attachment 
of dTDP-d-olivose	 (2ʹ,6ʹ-dideoxy-d-glucose) in urdamycin biosynthesis (Faust et al. 
2000). UrdGT2 was reported to also catalyze the O-glycosylation of an alternative 
aglycone substrate hydroxylated at a position analogous to the C-glycosylation site 
(Mittler et al. 2007). 
The mechanism of C-glycosylation by UrdGT2 was suggested to resemble the mechanism 
described for inverting glycosyltransferases in general and to involve a general base 
responsible for the deprotonation of the phenolic hydroxyl group of the substrate. The 
nucleophilic character of the adjacent carbon would then increase through resonance, 
which	would	enable	a	nucleophilic	attack	on	 the	activated	position	C-1ʹ	of	 the	 sugar	
(Mittler et al. 2007, Härle et al. 2011). Interestingly, both granaticin and medermycin 
are C-glycosylated at an analogous o-position, adjacent to a hydroxylated carbon of a 
phenol ring (Fig. 2).  
2.7 Regulatory genes in PnQ clusters 
The onset of antibiotic biosynthesis in Streptomyces species is highly controlled and linked 
to growth phase, morphological stage and nutritional conditions. Antibiotic production 
generally occurs after the vegetative growth phase; in solid media it coincides with the 
onset of the formation of the aerial hyphae, while in liquid media it generally occurs at a 
stationary phase (Doull & Vining 1990, Bibb 1996, Hopwood 2007). The presence of an 
easily assimilated carbon source, such as glucose, is known to often suppress antibiotic 
production, although other types of nutrients may have a similar effect. Actinorhodin 
production in S. coelicolor is actively suppressed in the presence of excess glutamate as 
a nitrogen source as well as in the presence of excess free phosphate (Doull & Vining 
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1990). Additionally, N-acetyl-glucosamine has a similar effect under certain conditions 
(van Wezel & McDowall 2011).  
Antibiotic biosynthesis and export from cells is controlled at transcriptional, translational 
and	post-translational	levels	by	both	pleiotropic	and	pathway-specific	regulator	genes.	
Furthermore, the production of some transcriptional regulators controlling antibiotic 
biosynthesis is known to be affected by secreted hormone-like signaling compounds, 
of which the best known are the A-factor-like g-butyrolactone compounds that act by 
binding to repressor proteins and thereby enabling the transcription of regulator genes 
(Bibb 1996, Hopwood 2007). The A-factor-like g-butyrolactones are widely distributed 
among Streptomyces species, and they can control both morphological differentiation 
and the production of many secondary metabolites, including actinorhodin production in 
S. coelicolor (Horinouchi et al. 1983, Takano et al. 2001). The A-factor of S. griseus acts 
by binding to an A-factor receptor protein ArpA, activating the transcription of a global 
regulator AdpA, which – in turn – acts both as a transcriptional activator and a repressor 
protein by binding to certain regulatory regions. A recent study on the AdpA regulatory 
network in S. griseus revealed the complexity of the regulation; the transcription of 
hundreds of genes was either up- or downregulated in the absence of AdpA (Higo et al. 
2012). 
Several global, pleiotropic regulators have been reported to control actinorhodin 
biosynthesis is S. coelicolor (van Wezel & McDowall 2011). The AfsK/AfsR/AfsS 
system involves a protein kinase AsfK responsible for the phosphorylation of the regulator 
AfsR. Phosphorylated AfsR activates the transcription of a small sigma-factor like 
protein	AfsS,	which	then	stimulates	the	expression	of	a	pathway-specific	transcriptional	
activator ActII-Orf4. Interestingly, a phosphate response-regulator system protein PhoP 
was recently suggested to act as a competitive transcriptional activator of afsS (Santos-
Beneit et al. 2011). 
Most	pathway-specific	regulator	proteins	are	transcriptional	activators	that	act	by	binding	
to	 specific	DNA	 regions	 upstream	of	 the	 biosynthetic	 genes,	 and	 the	 activator	 genes	
have been successfully utilized in over-expression experiments resulting in increased 
antibiotic	 production	 (Bibb	 1996).	 Many	 pathway-specific	 regulators	 belong	 to	 the	
family of Streptomyces antibiotic regulatory proteins (SARP), and the DNA-binding 
transcriptional activator ActII-Orf4 is one of the best characterized members of the 
family (Fernández-Moreno et al. 1991). Its gene contains a rare codon for leucine, TTA, 
which has a translational level regulatory role in actinorhodin production through the 
expression of a transfer-RNA gene bldA	specific	for	the	rare	codon	(UUA)	(Bibb	1996).	
Gra-Orf9 and Med-Orf11 encoded by genes in granaticin and medermycin clusters, 
respectively, are clear homologues of ActII-Orf4 (Ichinose et al. 1998, 2003). 
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Another type of transcriptional activator gene present in PNQ clusters is gra-orf20 
coding for a putative SoxR-like activator of the MerR DNA binding superfamily. Gra-
Orf20 was proposed to function by binding to certain conserved promoter sequences and 
activating the expression of a granaticin resistance gene in response to oxidative stress 
(Ichinose et al. 1998). Additionally, putative protein kinase regulator genes were found 
in granaticin and medermycin clusters (Ichinose et al. 2003). 
Negative regulator genes were also found, as a gene (actII-orf1) encoding a transcriptional 
regulator of the tetracycline repressor (TetR) family is present in the actinorhodin cluster. 
Structural studies of the repressor ActII-Orf1 (ActR) in complex with either dimeric 
actinorhodin or two molecules of the pathway intermediate S-DNPA suggested that, in 
addition to intracellular accumulation of the end-product, even the binding of a pathway 
intermediate	to	the	repressor	might	activate	the	transcription	of	the	actinorhodin	efflux	
pump gene actII-orf2 (actA) (Willems et al. 2008).
2.8 Conclusions
The biosynthetic steps of type II polyketides are generally understood relatively well, 
and PNQ biosynthetic studies have drawn attention – the biosynthetic studies on the 
model compound actinorhodin in particular. Consequently, high-resolution structures 
of several actinorhodin biosynthetic enzymes have been obtained, most of them during 
the past ten years (Table 1). As already evident from the literature review above, protein 
structural studies have shed light on the individual functions of the enzymes, and in many 
cases they have been central for increased understanding of the reaction mechanisms. 
Table 1. Reported structures of PNQ biosynthetic enzymes. NMR=nuclear magnetic resonance.
name Biosynthetic stage (description) method Reference
ActI-Orf1–Orf2 minPKS (KS–CLF heterodimer) X-ray Keatinge-Clay et al. 2004
ActI-Orf3 minPKS (ACP protein) NMR Crump et al. 1997
FrnN minPKS (ACP protein) NMR Li et al. 2003
ActIII PKS (C-9 ketoreductase) X-ray Hadfield	et al. 2004
ActVA-Orf6 tailoring (C-6 monooxygenase) X-ray Sciara et al. 2003
ActII-Orf1/ActR regulation (repressor protein) X-ray Willems et al. 2008
Despite the success of the enzyme activity and structural studies, many important pieces 
of evidence are still missing. A fundamental problem is the lack of sequence information 
on several biosynthetic gene clusters, as complete clusters have only been cloned for 
actinorhodin, granaticin and medermycin (Ichinose 2003), in addition to the alnumycin 
gene cluster characterized in this study. Furthermore, even the complete clusters harbor 
genes of unknown function, which might or might not be involved in PNQ biosynthesis. 
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The numerous unresolved questions related to PNQ biosynthesis include the identity of 
the enzymes catalyzing the putative reduction and dehydration steps during frenolicin 
starter unit formation, the possible protein–protein interactions and the role of ACP 
during	C-9	ketoreduction	and	 the	first	 ring	cyclization	 steps,	 the	number	of	common	
biosynthetic enzymes on frenolicin and nanaomycin pathways, and the mechanisms of 
the unusual C–C bond forming reactions. 
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3 AImS OF the StUdy
Initially, the main goal of the project was to identify the enzymes responsible for the 
formation and attachment of the unique dioxane moiety of alnumycin A and to use the 
gained knowledge about the biosynthetic steps in generation of novel natural products. 
In addition, studies related to enzymatic quinone formation on the alnumycin pathway 
were initiated as a side project. 
Later on, the emphasis shifted towards studying the molecular basis for dioxane 
biosynthesis,	 and	 the	 main	 goal	 became	 to	 understand	 how	 the	 identified	 enzymes	
catalyze each biosynthetic step. Structural information on two of the biosynthetic 
enzymes was obtained together with collaborators, and this information was also utilized 
in studying the unusual reaction mechanisms.  
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4 mAteRIALS And methOdS
A more detailed description of the experimental procedures can be found in the original 
publications I–IV.
4.1 Reagents
ABTS (2,2’-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt, 98%, 
Fluka), catalase (from bovine liver, Biochemika), glucose oxidase from Aspergillus 
niger (Fluka), NADH disodium salt hydrate (98%), NADPH tetrasodium salt (96%), 
peroxidase from horseradish (Fluka), d-ribose-5-phosphate disodium salt hydrate 
(98%) and d-ribulose-5-phosphate disodium salt (96%) were all purchased from Sigma-
Aldrich. [U-13C] d-ribose (98%), [5-13C] d-ribose (99%) and [1-13C] d-ribose (99%) were 
purchased from Cambridge Isotope Laboratories, Inc.
4.2 Bacterial strains and culture conditions
Alnumycin A producing Streptomyces sp. CM020 was obtained from Galilaeus Oy 
(Kaarina, Finland). Streptomyces albus (Chater & Wilde 1980) was used as a host 
strain for the heterologous expression of the gene cluster. Transformation of S. albus by 
intergeneric conjugation was conducted using E. coli ET12567/pUZ8002 (Kieser et al. 
2000). Tryptone soy broth was used as a liquid medium and MS (Kieser et al. 2000) as 
a solid medium for Streptomyces species. For the production of secondary metabolites, 
Streptomyces	 strains	 were	 routinely	 cultivated	 in	 25	 mL	 of	 modified	 E1	 medium	
(Ylihonko et al.	1994)	with	starch	left	out	and	Pharmamedia	replaced	by	soy	flour,	for	
5 days at 300 rpm, 301 K. Amberlite XAD 7HP (Rohm and Haas) was included for the 
adsorption	of	metabolites	(1	g/50	mL).	Apramycin	at	50	μg/mL	and	thiostrepton	at	50	
μg/mL	and	40	μg/mL	were	used	for	selection	in	solid	and	liquid	media,	respectively.
E. coli strains XL1-Blue MRF’ (Stratagene) and TOP10 (Invitrogen) were used for 
cloning purposes, and the latter strain for protein production purposes. E. coli strains 
were cultivated in Luria-Bertani (LB) or 2 × tryptone yeast (TY) medium supplemented 
with appropriate antibiotics for the selection of plasmids and cosmids. 
4.3 dnA techniques and sequence analysis
The isolation of DNA from Streptomyces species was performed using conventional 
techniques (Kieser et al. 2000). Restriction enzyme-digested fragments were recovered 
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from agarose gels using either a QIAquick or an E.Z.N.A. gel extraction kit (Qiagen 
or Omega Bio-Tek), whilst plasmid DNA from E. coli was isolated using a QIAprep 
Spin Miniprep Kit (Qiagen) or an E.Z.N.A. plasmid mini kit (Omega Bio-Tek). Phusion 
DNA Polymerase (Finnzymes) was used for polymerase chain reactions (PCRs) with 3 
or	5%	dimethyl	sulfoxide	(DMSO)	to	facilitate	the	amplification	of	GC-rich	template	
sequences.
For the cloning of the alnumycin gene cluster, a genomic library of partially digested 
Streptomyces sp. CM020 DNA was constructed using a cosmid vector pFD666 and a 
Gigapack III XL (Stratagene) kit for packaging. After screening, one of the colonies was 
chosen for the sequencing of the insert DNA, which was further cloned into an E. coli 
– Streptomyces shuttle vector pKC505 (Kieser et al.. 2000) as a ca. 30-kbp fragment for 
heterologous expression in Streptomyces species. In order to enable the transformation 
of Streptomyces species by conjugation, the aac(3)IV region of the construct was 
substituted by an aac(3)IV oriT fragment including the oriT origin of replication, which 
was generated by PCR using pSET152 (Kieser et al..	2000)	as	a	template.	The	λ	Red	
recombinase system (Datsenko & Wanner 2000) utilizing homologous recombination 
was used for the substitution and the resulting cosmid was named pAlnuori (I).   
The ORFs aln3, aln4, aln5, aln6, alnH and alnT were individually deleted, and the 
overlapping ORFs alnA and alnB	 co-deleted	 from	 the	 cosmid	 pAlnuori	 using	 the	 λ	
Red recombinase system (Datsenko & Wanner 2000)  through a two-step homologous 
recombination process. The primers used for inactivation consisted of a 50-nt region 
homologous to the target sequence followed by a 20-nt priming sequence for the 
amplification	of	the	cmR	gene	with	flanking	FRT	(FLP	recognition	target)	sites	(I–III).	
The	λ	Red	recombinase	was	utilized	for	the	first	recombination	step,	while	the	elimination	
of the resistance gene was executed using the helper plasmid pFLP2 expressing the FLP 
enzyme (Hoang et al. 1998). 
DNA	 sequencing	 was	 mainly	 performed	 at	 Eurofins	 MWG	 Operon,	 Germany.	 The	
sequence analysis program Artemis (Rutherford et al.	2000)	was	used	for	the	identification	
of ORFs. Comparisons to known DNA and aa sequences were performed using the 
Basic Local Alignment Search Tool (BLAST) of the National Center for Biotechnology 
Information (NCBI), USA.    
4.4	 Protein	production	and	purification
For	protein	production	purposes,	individual	genes	were	cloned	into	a	modified	pBADHisB	
(Invitrogen) vector (Kallio et al. 2006). All polyhistidine-tagged recombinant proteins 
carrying an N-terminal (M)AHHHHHHHRS-sequence were produced in E. coli TOP10 
in 2 × YT medium, where l-arabinose	was	added	to	a	final	concentration	of	0.02%	(w/v,	
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0.006–0.01% for Aln4) at OD600 = 0.5–0.7 for induction. The co-expression of chaperones 
encoded	by	pG-KJE8	(Takara	Bio	Inc.)	significantly	increased	the	yield	of	His7-Aln4 in 
the soluble fraction, and the induction of chaperone production was accomplished by the 
addition of 5 ng/ml of tetracycline into E. coli TOP10/pBADHisBdaln4 cultures at an 
OD600 = 0.2–0.3. After induction, the cultures were grown at 295 K overnight, harvested 
at 277 K and lysed using French Press or ultra sound sonication. Triton X-100 was then 
routinely	added	to	a	final	concentration	of	0.5%	(v/v).	
For	 purification	by	 affinity	 chromatography,	 the	 crude	 extracts	were	 either	 incubated	
with	Talon	Cobalt	affinity	 resin	 (Clontech),	 loaded	onto	a	1	mL	HIS-select	Cartridge	
(Sigma, AlnA) or onto a 5 mL HisTrap Ni2+-affinity	column	(Aln4,	AlnH,	AlnT)	as	part	
of an ÄKTA FPLC (Fast Protein Liquid Chromatography) system (GE Healthcare), and 
the target proteins were eluted with increasing concentrations of imidazole. AlnH was 
further	purified	by	anion	exchange	using	a	6	mL	RESOURCE	Q	column	(GE	Healthcare).	
The main elution fractions were subjected to buffer exchange using a PD-10 column (GE 
Healthcare), concentrated using a Centriprep YM-10 device (Millipore) and frozen in 
50% (v/v) glycerol. Protein concentrations were typically estimated by Bradford assay 
(Bradford 1976). 
4.5 enzyme activity assays
Reactions	 were	 set	 up	 in	 a	 dilute	 buffer	 and	 ≥	 10%	 glycerol	 and	 premixed	 before	
alnumycin substrates were added in 2 –5% DMSO to start the reactions. For all enzymes 
except for Aln6, the oxygen concentration was reduced using the glucose oxidase – 
catalase system in 60 mm d-glucose	(III,	IV).	For	specific	conditions	used	for	AlnH	and	
AlnT, see publication II.
The incubation period of up to 3.5 h at 288 K (296 K for Aln6) was typically followed by 
extraction with CHCl3. The CHCl3 extracts were air-dried and dissolved in acetonitrile 
for HPLC (high-performance liquid chromatography) analysis by a SCL-10Avp system 
equipped with a SPD-M10Avp diode array detector (Shimadzu), and either a LiChroCART 
250-4	RP-18	column	(5	μm,	Merck),	eluted	with	20	mm aqueous ammonium acetate and 
a	55–100%	acetonitrile	gradient,	or	a	SunFire	C18	column	(3.5	μm,	Waters)	eluted	with	
0.1% aqueous formic acid and a 15–100% acetonitrile gradient. 
Alternatively, analysis of the reaction products of AlnA was performed by separation of 
the	acidified	(2.5%	HCOOH)	reaction	mixture	on	a	Discovery	DSC-18	column	(100	mg,	
Supelco) in 0.1% HCOOH. The DSC-18 elution fractions in methanol were analyzed 
by	HPLC	using	a	Discovery	HSC18	column	(5	μm,	5	cm	×	4.6	mm,	Supelco)	eluted	
with 20 mm aqueous ammonium acetate pH 3.6 and a 70–100% methanol gradient. 
Coupled AlnA and AlnB reactions with enzyme variants were followed by end-point 
 Materials and Methods 
34
assays of both solvent phase samples analyzed by quantitative HPLC and water phase 
samples analyzed by the Malachite green method, which is based on the detection of free 
phosphate (Geladopoulos et al. 1991).
4.6	 Production,	purification	and	structural	elucidation	of	secondary	
metabolites
For large scale production of secondary metabolites, the XAD 7HP resin from a total 
of 3 to 4 L of Streptomyces cultivations was separated by repeated washing with tap 
water and decanting. Compounds were then extracted from the resin applied on an XAD 
7HP column using an aqueous acetonitrile or isopropanol gradient. Preparative scale 
purification	of	 secondary	metabolites	 typically	 included	chloroform	extractions,	open	
column	chromatography	with	silica	gel	and	a	final	polishing	step	by	preparative	HPLC	
with a Merck Hitachi L-6200A (I–IV).  
Structural	analysis	of	the	purified	secondary	metabolites	and	in vitro reaction products 
was accomplished using Bruker Avance NMR spectrometers, and the molecular 
formulae	were	confirmed	by	high	resolution	mass	spectrometry	with	either	ZABSpec	
(VG Analytical) or micrOTOF-Q (Bruker) mass spectrometers (I–IV). 
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5 ReSULtS And dISCUSSIOn
5.1 Analysis of the alnumycin gene cluster (I)
The alnumycin A producing Streptomyces sp. CM020 was obtained from Galilaeus 
Oy (Kaarina). The alnumycin gene cluster was cloned, sequenced and heterologously 
expressed in the S. albus	 host	 strain	 (Chater	&	Wilde	1980),	which	confirmed	 that	 a	
complete cluster had been isolated. Sequence analysis of the 30-kbp insert fragment 
enabled	 straightforward	 identification	 of	 early	 biosynthetic	 genes	 likely	 to	 code	 for	
starter	unit	and	minPKS	enzymes,	C-9	ketoreductase	and	the	first	two	cyclases,	based	
on a relatively high aa sequence similarity to known PNQ biosynthetic gene products. 
Furthermore,	 sequence	 analysis	 enabled	 the	 preliminary	 identification	 of	 putative	
regulatory and transport proteins (Fig. 8, I).
The starter unit ketoacyl synthase gene alnI was found to reside separate from other early 
biosynthetic	genes,	with	the	last	four	base	pairs	(GTGA)	overlapping	with	the	5ʹ-end	of	
a tailoring stage gene alnH in a manner suggestive of translational coupling. Frenolicin 
and R1128 starter unit ketoacyl synthases FrnI from S. roseofulvus (76% similarity) and 
ZhuH from Streptomyces sp. R1128 (72% similarity) are among the closest homologues 
of AlnI. The starter unit ACP gene alnJ and the acyl transferase gene alnK were found to 
reside	next	to	each	other	but	in	opposite	orientations,	with	the	3ʹ-ends	overlapping	by	19	
base pairs (Fig. 8). The highest sequence similarity to AlnJ was found for the frenolicin 
starter unit ACP FrnJ (73%) and, again, the starter unit ACP ZhuG from Streptomyces sp. 
R1128 was among the closest homologues. Slightly lower sequence similarity was found 
between the deduced starter unit acyl transferase AlnK and its homologues on frenolicin 
and R1128 pathways (I). 
Figure 8. The organization of the alnumycin gene cluster. Deduced biosynthetic stage for each 
gene	product	is	color-coded	(modified	from	III).			
In vivo cross-complementation of a benastatin starter unit synthase mutant by the co-
expression of alnI, alnJ and alnK was reported to result in the enhanced production 
of butyrate-primed compounds. Thus, the combinatorial biosynthesis of benastatin 
derivatives	verified	the	deduced	role	of	the	alnumycin	starter	unit	genes	in	the	biosynthesis	
of a four-carbon starter unit (Xu et al. 2009).   
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High sequence similarity to frenolicin biosynthetic enzymes – and to other PNQ 
biosynthetic gene products – was also found for the deduced KS AlnL, CLF AlnM, ACP 
AlnN,	first	ring	cyclase	AlnQ,	second	ring	cyclase	AlnR	and	C-9	ketoreductase	AlnP.	
Furthermore, sequence analysis of the cloned cluster revealed that as many as seven 
of the thirty ORFs are likely to code for regulator proteins (Fig. 8), of which AlnR3 
is a clear homologue of the SARP-family activators ActII-Orf4, Gra-Orf9 and Med-
Orf11. Interestingly, actII-orf4 and alnR3 contain the rare codon for leucine (TTA) as 
the	fifth	or	sixth	codon,	respectively,	while	gra-orf9 and med-orf11 do not contain TTA-
codons. Thus, even AlnR3 expression is likely to be regulated at a translational level via 
the	expression	of	transfer-RNA	specific	for	the	rare	codon (Bibb 1996). The remaining 
deduced regulator genes consist of two pairs of sensory kinase/response regulator genes 
(alnR4/alnR5 and alnR7/alnR6), and alnR8 and alnR2 coding for putative MarR- and 
TetR-family DNA-binding proteins (I).  
The total number of putative regulatory genes was higher than in the closely related 
actinorhodin, granaticin and medermycin clusters with 2, 6 and 5 deduced regulator 
genes, respectively (Ichinose et al. 2003). However, the exact number of regulator genes 
in	the	clusters	has	not	been	confirmed,	as	some	of	the	deduced	regulators	might	not	be	
involved in PNQ biosynthesis and, on the other hand, some genes of unknown function 
or not residing in the cloned fragments might have a regulatory role.
5.2 Gene products responsible for pyran ring formation (I, III)
On	the	basis	of	gene	inactivation	experiments,	Aln4	and	Aln5	were	identified	as	gene	
products likely to be involved in pyran ring formation. Accumulation of the early 
shunt product K1115 A with an incorrectly cyclized third ring (Fig. 9) in aln4 and aln5 
deletion mutant strains suggested that the gene products might be involved in pyran ring 
formation (I).
Aln4 of the aldo-keto reductase (AKR) superfamily showed the highest sequence 
similarity to uncharacterized proteins from Streptomyces chartreusis NRRL 12338 and 
Sanguibacter keddieii DSM 10542. Aln5, on the other hand, was deduced to possess 
a conserved lipocalin-like domain, but the exact function was not known for any of 
the	homologous	proteins.	Interestingly,	it	showed	significant	sequence	similarity	(47%)	
to the C-terminal domain of a modular polyketide synthase StiJ from Stigmatella 
aurantiaca, which was proposed to catalyze chromone ring formation (Gaitatzis et al. 
2002). Consequently, it was suggested that Aln4 might function as a C-15 ketoreductase 
and Aln5 as a cyclase responsible for pyran ring formation (I). 
Later on, a minor secondary metabolite product of the aln4 mutant strain was isolated 
from the aln3	deletion	mutant	strain,	and	the	metabolite	–	alnumycin	B	–	was	verified	
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to be a late pathway intermediate. Furthermore, Aln4 was shown to be essential for 
dioxane formation and to catalyze the reduction of the dioxolane unit of alnumycin 
B (III). Currently it remains unclear whether Aln5 alone is responsible for pyran ring 
formation on the alnumycin pathway.
5.3 the Alnt/Alnh monooxygenase system is essential for p-quinone 
formation (II) 
Sequence analysis pointed out AlnT (413 aa) and AlnH (180 aa) as a probable two-
component system responsible for quinone formation via C-8 oxygenation (reversed 
biosynthetic numbering) on the alnumycin pathway. AlnT belongs to an ACAD (acyl-
CoA dehydrogenase) superfamily with 63% sequence similarity to ActVA-Orf5 from S. 
coelicolor	A3	(2),	while	AlnH	belongs	to	a	FlaRed	(flavin	reductases)	superfamily	with	
65% sequence similarity to ActVB from S. coelicolor A3 (2). As the two-component 
monooxygenase system ActVA-Orf5–ActVB was previously shown to catalyze both 
C-8 hydroxylation and C-6 oxygenation on the actinorhodin pathway (Fig. 6, Valton et 
al. 2006, Okamoto et al. 2009), AlnT was deduced to catalyze C-8 oxygenation. The role 
of the reductase component AlnH/ActVB is to provide AlnT/ActVA-Orf5 with reduced 
flavin,	which	then	reacts	with	molecular	oxygen	to	form	a	hydroperoxide	intermediate	
utilized as an oxidant (Valton et al. 2006, II).
Individual inactivation of alnH or alnT resulted in strikingly similar secondary metabolite 
profiles.	 Large-scale	 production	 and	 purification	 of	 the	 metabolites	 revealed	 that,	 in	
addition to previously characterized anthraquinones K1115 A (Naruse et al. 1998) and 
DHPA (1,6-dihydroxy-8-propylanthraquinone, Huang et al. 2006), a novel compound 
named thalnumycin A was also produced (Fig. 9). K1115 A and its decarboxylated 
form DHPA are both oxygenated at position C-6, possibly non-enzymatically, while 
thalnumycin A is not oxygenated at either position C-6 or C-8 (reversed biosynthetic 
numbering, II). A similar lack of oxygenation was reported for actinoperylone (Fig. 4) 
produced by a DactVA-orf5,6 double mutant strain (Okamoto et al. 2009). 
The inactivation of either actVB or actVA-orf5 in S. coelicolor was previously shown 
to result in the accumulation of secondary metabolites with correctly formed pyran 
rings (Cole et al. 1987, Okamoto et al. 2009). Surprisingly, none of the characterized 
metabolites of the alnH and alnT deletion mutant strains possessed a correctly formed 
pyran ring (Fig. 9), indicating that the oxygenation leading to quinone ring formation 
occurs prior to third ring formation on the alnumycin pathway, which clearly differs 
from the timing of these events on the actinorhodin pathway (II). 
The	 regiospecificity	 of	 the	 hydroxylation was demonstrated in vitro through the 
conversion of thalnumycin A into thalnumycin B by the AlnT–AlnH system utilizing 
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NADH and FMN (Fig. 9). Enzymatically produced thalnumycin B was found to be 
relatively	 unstable,	 but	 it	 could	 be	 isolated	 in	 a	 sufficient	 quantity	 to	 enable	 partial	
structural	characterization	by	NMR,	which	confirmed	the	p-hydroquinone structure of 
the	first	ring	(II).
Figure 9. A model for the C-8 hydroxylation catalyzed by the two-component monooxygenase 
AlnT-AlnH. Structures of the secondary metabolites thalnumycin A, K1115 A and DHPA, 
produced by alnH and alnT deletion mutant strains, are shown. 




glycosidases YeiN and TM1464 from E. coli and Thermotoga maritima are the only 
members of the protein family that have a known function, and are reported to catalyze 
both the hydrolysis of a glycosidic C–C bond and the reverse C–C bond formation between 
uracil and d-ribose-5-phosphate (Preumont et al. 2008). AlnB (227 aa), on the other hand, 
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was deduced to belong to the HAD (haloacid dehalogenase) superfamily and catalyze 
phosphate transfer or dephosphorylation (Allen & Dunaway-Mariano 2004).
Initial assignment of AlnA and AlnB as enzymes involved in the biosynthesis or 
attachment of the dioxane moiety was based on in vivo mutagenesis studies. Co-deletion 
of the overlapping ORFs from the cloned gene cluster completely abolished alnumycin A 
production, and the mutant strain was found to produce a novel compound, prealnumycin, 
lacking the dioxane unit. Expression of either gene alone could not complement the 
deletion	(I).	Later	on,	it	was	confirmed	that	the	individual	inactivation	of	either	of	the	
two	genes	resulted	in	a	similar	production	profile	(unpublished	results).	
The individual roles of the enzymes AlnA and AlnB in dioxane biosynthesis remained 
unknown until several pieces of experimental evidence suggested that the biosynthetic 
origin of the unique dioxane moiety might be d-ribose. The inactivation of an ORF aln6 
was found to result in the accumulation of alnumycin C and alnumycin D containing a 
ribose moiety attached to the prealnumycin aglycone, and even a single point mutation in 
alnB was found to result in the accumulation of the same compounds. The ribose moiety 
was found in furanose form in alnumycin C and in pyranose form in alnumycin D, and 
the former compound was isolated as an anomeric pair of stereoisomers only differing in 
the	configuration	of	position	C-1ʹ.	Of	these	metabolites,	only	the	β-anomer	of	alnumycin	
C was reported earlier under the name anhydroexfoliamycin (Volkmann et al. 1995, III). 
Furthermore, the heterologous expression construct S. albus/pAlnuori carrying the 
complete alnumycin cluster was found to produce alnumycin C and D prior to the 
end	product	during	 the	first	days	of	cultivation,	which	suggested	 that	 the	compounds	
might be pathway intermediates (unpublished results). To study the role of d-ribose 
in dioxane biosynthesis, feeding experiments using 1-13C-, 5-13C- and universally 
13C-labeled d-ribose were conducted, and NMR-based analysis of the incorporation 
patterns	of	partially	purified	alnumycin	A	suggested	that	the	complete	dioxane	moiety	
was synthesized from ribose or a closely related metabolite (III). 
The	role	of	alnumycin	C	as	a	pathway	intermediate	was	confirmed	by	in vitro synthesis of 
the compound using the two enzymes AlnA and AlnB with prealnumycin and d-ribose-
5-phosphate as substrates. Curiously, alnumycin D was co-produced in vitro only in the 
presence of NAD(P)H (III). At high d-ribose-5-phosphate concentrations prealnumycin 
appeared to be consumed even by AlnA alone, although initially no reaction products 
could be observed. Due to the poor solubility and stability of the compound, the AlnA 
reaction product was found problematic to extract, analyze and purify, but an NMR 
sample	of	sufficient	quality	was	obtained.	The	product	alnumycin	P	was	verified	to	contain	
a phosphorylated ribose unit attached via a C–C bond to position C-8 of prealnumycin, 
and it was isolated as an anomeric pair of stereoisomers analogous to alnumycin C (IV).
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After the assignment of AlnA as a C-glycosynthase catalyzing attachment of d-ribose-
5-phosphate, or an alternative substrate d-ribulose-5-phosphate, the biosynthetic role 
of	the	phosphatase	homologue	AlnB	was	more	straightforward	to	confirm.	The	in vitro 
dephosphorylation	of	purified	alnumycin	P	to	alnumycin	C	by	AlnB	alone	confirmed	the	
expected function of AlnB as a phosphatase (IV).  
5.4.2 the structure of the C-glycosynthase AlnA (Iv)  
The 2.1-Å X-ray crystal structure of AlnA was determined by molecular replacement 
using the TM1464 from T. maritima (Levin et al. 2005) as a search model. AlnA was 
found	to	be	folded	into	an	α/β/α	domain	involving	a	twisted,	nine-stranded	mixed	β-sheet	
surrounded	be	 three	α-helices	 on	 one	 side	 and	 four	 α-helices	 on	 the	 other	 side.	Two	
additional	β-strands,	a	metal	ion	and	a	small	lid-like	helix-turn-helix	motif	were	observed	
on	top	of	the	β-sheet.	A	structural	similarity	search	revealed	that	AlnA	is	significantly	
similar	 in	 structure	only	 to	 the	pseudouridine-5ʹ-phosphate	glycosidase	TM1464,	and	
both proteins were found to crystallize in a trimeric form (Levin et al. 2005, IV).
A 3.15-Å structure of a complex with a phosphorylated sugar bound to the putative active 
site was obtained by soaking AlnA crystals in 100 mm d-ribose-5-phosphate. The electron 
density	for	the	observed	ligand	was	found	to	best	fit	to	d-ribulose-5-phosphate, which is 
an alternative substrate for AlnA, or a linear aldehyde form of d-ribose-5-phosphate. The 
binding of the linear d-ribulose-5-phosphate	by	AlnA	was	also	confirmed	using	NMR	
based methods. The phosphate moiety was found to be coordinated to His130, Ser140 
and to the metal ion, which is most likely Ca2+ (IV). Interestingly, a relatively similar 
unidentified	ligand,	larger	than	glycerol-3-phosphate,	was	observed	in	the	1.9-Å	crystal	
structure of TM1464 (Levin et al. 2005).
5.4.3 the structure of the phosphatase AlnB (Iv)
The 1.25-Å crystal structure of AlnB was determined by molecular replacement using 
the core domain of a putative phosphatase from Haemophilus somnus as a search model. 
AlnB	was	 found	 to	 consist	 of	 a	modified	Rossmann	 fold	 domain	 similar	 to	 the	 core	
domain of other members of the HAD family, and of a four-helix bundle cap domain. 
Based	 on	 the	 structure	 of	 the	 cap	 domain,	AlnB	 could	 be	 classified	 as	 a	member	 of	
subfamily I (Allen & Dunaway-Mariano 2004). A metal ion, most likely Mg2+, was 
observed in the junction between the core and cap domains, and the residues Asp15, 
Asp175 and the backbone carbonyl oxygen of Asp17 were found to be involved in the 
coordination of the metal ion (IV). 
In HAD family proteins, the catalytic platform is created by core domain residues, 
while the cap domain is considered important for substrate recognition. On the 
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other hand, the lack of a cap domain, which is observed for enzymes of subfamily 
III, enables the binding of larger substrates (Allen & Dunaway-Mariano 2004). 
The substrate of AlnB, alnumycin P (Fig. 10), is relatively large for a subfamily I 
enzyme but could be modeled inside a narrow cavity within the four-helix bundle, 
with the phosphate moiety next to the metal ion, as observed in the complex with 
free phosphate (IV).  
5.4.4 Proposed mechanism for C-ribosylation (III, Iv)
AlnA was found to catalyze the slow interconversion of d-ribose-5-phosphate and 
d-ribulose-5-phosphate in solution, which occurs via a linear ene-diol species (IV). This 
finding,	together	with	the	observed	linear	phosphosugar	in	the	complex	structure	of	AlnA,	
and the ability of both d-ribose-5-phosphate and d-ribulose-5-phosphate to serve as 
substrates for AlnA (III), provided strong evidence for a mechanistic proposal involving 
a linear phosphosugar species as a substrate for the C-ribosylation of prealnumycin (Fig. 
10, IV). 
Figure 10. Proposed mechanism for C-ribosylation of prealnumycin by AlnA and AlnB. Selected 
active	site	residues	of	AlnA	(upper	part)	and	AlnB	(lower	part)	are	shown	in	bold	(modified	from	
IV).
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In the initial step, Glu29 is suggested to act as a general base and abstract a proton of 
a	hydroxyl	group	at	position	C-2ʹ	of	the	ene-diol	intermediate.	The	observed	distance	
(4.3	Å)	between	Glu29	and	 the	probable	C-2ʹ	oxygen	 in	 the	AlnA	complex	structure	
might be small enough to support this catalytic role for Glu29. The formed enolate anion 
would be resonance-stabilized and able to act as a nucleophile attacking the position 
C-8 of prealnumycin in a manner characteristic of a Michael-type addition mechanism 
to	an	α,β-unsaturated	carbonyl	compound.	The	intermediate	anion	formed	at	 this	step	
could be stabilized by ionic interaction with Lys86 or protonated. Cyclization of the 
attached sugar might then occur even non-enzymatically, resulting in the formation of 
alnumycin P (IV). Condition-dependent formation of alnumycin D by AlnA and AlnB 
in vitro (III) supports the proposed model for spontaneous cyclization, although in the 
case of alnumycin D dephosphorylation of the open-chain intermediate (Fig. 10) should 
occur prior to cyclization. 
A Michael-type 1,4-addition mechanism was supported by the mutagenesis of AlnA 
active site residues. The enzymatic activity assays with AlnA variants were performed 
as coupled end-point assays, and they revealed close to complete inactivation of AlnA 
by the mutagenesis of Glu29 to Gln. In addition, the activities of the alanine variants of 
Glu29, Lys159 and Lys86 were found to be relatively low (IV).
In general, the mechanism proposed for AlnA does not resemble the mechanisms 
described for known prokaryotic glycosyltransferases, which involve a nucleophilic 
attack on the activated position of an NDP-sugar (Thibodeaux et al. 2007, Chang et 
al. 2011). In contrast, it is the sugar species that acts as a nucleophile in the proposed 
C-ribosylation mechanism (Fig. 10, IV). 
Dephosphorylation of alnumycin P to alnumycin C by the phosphatase AlnB was 
suggested to involve the putative catalytic residues Asp15 and Asp17, which was 
supported by the mutagenesis of these residues. The relative activity of AlnB 
variants was measured in a coupled assay with AlnA, and the individual mutagenesis 
of the conserved Asp15 and Asp17 to alanine residues was found to result in close 
to inactive AlnB. Asp17 is likely to act as a general acid/base, which protonates the 
leaving	group	–	in	this	case	the	C-5ʹ	oxygen	of	alnumycin	P.	Asp15,	in	turn,	is	likely	
to be responsible for a nucleophilic attack on the phosphorus. In the next step, Asp17 
may	act	as	a	general	base	and	aid	in	the	generation	of	a	final	nucleophile	from	water.	
The mutagenesis of Lys119 to an alanine or arginine residue reduced the enzyme 
activity	to	only	about	4%	vs.	2%.	Based	on	modeling	results,	the	finding	may	be	due	
to an effect on the binding of the substrate (IV). In general, the mutagenesis results 
were well in line with other phosphatases of the HAD family (Allen & Dunaway-
Mariano 2004).
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5.5 Aln6 is a novel riboisomerase (III)
5.5.1 the function of Aln6 (III)
Inactivation of the ORF aln6	was	essential	for	the	identification	of	Aln6	(359	aa)	as	a	
dioxane biosynthetic enzyme, as functions are not known for any of the homologous 
proteins. Interestingly, these include ActVA-3 from S. coelicolor A3 (2), Gra-Orf28 
and Gra-Orf30 from S. violaceoruber, as well as Aln7 from the alnumycin gene cluster. 
Aln6 was found to be essential for dioxane biosynthesis, as deletion of the aln6 gene 
abolished the production of alnumycin A, and the mutant strain S. albus/pAlnuoriDaln6 
accumulated novel C-ribosylated compounds alnumycin C and alnumycin D (III, see 
section 5.4.1). 
The in vitro enzymatic conversion of alnumycin C to alnumycin B carrying a dioxolane 
unit	in	place	of	a	ribose	unit	confirmed	the	biosynthetic	role	of	Aln6.	Alnumycin	D,	on	
the other hand, could not be converted by Aln6. Unexpectedly, no apparent cofactors 
were necessary for the oxidative conversion, although Aln6 was found to consume 
molecular oxygen and produce hydrogen peroxide during the conversion of alnumycin 
C	(Fig.	11).	Based	on	these	findings,	Aln6	could	be	classified	as	a	novel	riboisomerase	
or a novel cofactorless oxidase (III).
5.5.2 Proposed mechanism for dioxolane formation (III)
The oxidative conversion of the ribose unit in alnumycin C into the dioxolane unit of 
alnumycin	B	 involves	 cleavage	of	 a	C–C	bond.	The	 cleavage	 site	was	 confirmed	by	
feeding experiments with labeled d-ribose species; 1-13C- and 5-13C-carbons of ribose 
were	specifically	incorporated	into	positions	C-1ʹ	and	C-5ʹ	of	alnumycin	B	(Fig.	11,	III).	
The labeling experiments, together with the stoichiometric consumption of molecular 
oxygen, detected production of hydrogen peroxide and the changes observed in the UV-
Vis spectrum of the alnumycins enabled a mechanistic proposal for dioxolane formation. 
In	the	initial	step,	deprotonation	at	position	C-1ʹ	was	suggested	to	lead	to	the	formation	
of a highly conjugated intermediate with a UV-Vis spectrum likely to differ from the 
distinctive alnumycin spectrum. The intermediate anion could then react with oxygen to 
form a hydroperoxy intermediate. Loss of hydrogen peroxide would generate a double 
bond	between	C-1ʹ	and	C-2ʹ,	and	a	following	hydration	step	would	yield	a	hydroxylated	
intermediate. Up to this stage, the mechanism would be similar to the well-characterized 
hydroxylation mechanism of urate oxidase, which is a cofactorless oxidase (Gabison 
et al. 2008). Subsequent ring opening and tautomerization steps would enable an aldol 
cleavage	 of	 the	 C-1ʹ–C-2ʹ	 bond.	 The	 dioxolane	 unit	 could	 then	 be	 formed	 through	
hemiacetal and acetal formation steps (Fig. 11, III). 
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Figure 11. Proposed mechanism for dioxolane formation by Aln6. Only the quinone ring of the 
prealnumycin moiety is shown. Carbon numbering is given for the ribose unit in the substrate 
alnumycin	C	and	for	the	dioxolane	unit	in	the	product	alnumycin	B	(modified	from	III).
5.6 the reductase Aln4 catalyzes the conversion of dioxolane to dioxane 
(I, III)    
Aln4 (354 aa) belongs to a family of NAD(P)H-dependent aldo-keto reductases (AKRs) 
deduced to catalyze a reduction of an aldehyde or ketone to an alcohol. Initially, Aln4 
was assigned as a C-15 ketoreductase involved in pyran ring formation, based on the 
secondary	metabolite	 profile	 of	 the	 aln4 mutant strain; inactivation of aln4 resulted 
in complete abolishment of alnumycin A production, and accumulation of the shunt 
product K1115 A together with relatively low levels of an unknown side product (I). 
The minor metabolite, alnumycin B, was later characterized and found to consist of a 
highly unusual dioxolane (cis-bicyclo[3.3.0]-2′,4′,6′-trioxaoctan-3′β-ol)	moiety	attached	
via	a	C-1ʹ–C-8	bond	to	the	prealnumycin	aglycone	(Fig.	11).	In	a	manner	analogous	to	
alnumycin P and alnumycin C, the compound was again isolated as an epimeric pair of 
stereoisomers	only	differing	at	position	C-1ʹ	(III).
The ORF aln4 was found to be separated by only 3 bp from the upstream ORF aln3. 
Curiously, the aln3 mutant strain was found to only produce low levels of alnumycin 
A, and alnumycin B as its main secondary metabolite. The relatively high levels of 
alnumycin B produced suggested that aln3 might be involved in a late biosynthetic step, 
but no additional evidence supporting a possible biosynthetic role for aln3 was obtained 
(III). 
The enzymatic in vitro	conversion	of	alnumycin	B	to	alnumycin	A	by	Aln4	confirmed	the	
biosynthetic role of Aln4 as an NADPH-dependent reductase catalyzing the conversion 
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of a dioxolane unit into the dioxane unit of alnumycin A. Additionally, a novel in vitro 
side product, alnumycin S, was isolated and found to contain the dioxolane moiety 
reduced	at	position	C-3ʹ	(numbering	for	alnumycin	B).	Aln4	was	thus	verified	to	catalyze	
the reduction of the open-ring aldehyde form of alnumycin B to an alcohol (Fig. 12, III).
Figure 12. A model for dioxane formation by Aln4. The formation of the in vitro side product 
alnumycin S is shown in brackets. The incorporation of the 5-13C d-ribose label into the dioxolane 
unit	of	alnumycin	B	and	the	dioxane	unit	of	alnumycin	A	is	marked	with	asterisks	(modified	from	
III).
An additional ring opening is necessary for the formation of the 6-membered dioxane ring 
from dioxolane. As alnumycin S could not be converted further by Aln4, it is plausible 
that the ring opening needs to take place prior to the reduction step. The ring opening 
would putatively occur through the hydration of the acetal, resulting in two alternative 
aldehyde	products,	which	could	then	be	reduced	by	Aln4.	A	final	acetal	formation	step	
would result in a dioxane product. The mechanistic proposal was supported by feeding 
experiment results, which revealed that the 5-13C-label of d-ribose was incorporated into 
two alternative positions in the end product alnumycin A (Fig. 12, III).  
The recent characterization of the stereoisomers of the end product alnumycin A (Oja et 
al. 2012, Tähtinen et al. 2012, see section 2.2) is in line with the proposed mechanism 
for	 Aln4.	 Although	 the	 suggested	 mechanism	 does	 not	 require	 any	 configurational	
changes	at	positions	C-4ʹ	or	C-5ʹ	(numbering	for	alnumycin	A),	these	might	occur	e.g.	
via the tautomerization of an open-chain aldehyde intermediate (Fig. 12). However, 
more	detailed	biosynthetic	and	mechanistic	studies	would	be	necessary	to	confirm	the	
biosynthetic origin of the stereoisomers of alnumycin A. 




to the understanding of alnumycin biosynthesis, in particular to the understanding of 
the dioxane biosynthetic steps. The main results include functional analysis of the 
two-component monooxygenase AlnH–AlnT, which is responsible for the enzymatic 
oxygenation of the polyketide aglycone, and characterization of the dioxane biosynthetic 
pathway involving the enzymes AlnA, AlnB, Aln6 and Aln4 (Fig. 13). 
Figure 13. A model for the alnumycin biosynthetic pathway. For simplicity, the stereoisomers of 
alnumycins A, B, C and P are not shown. 
Most of the enzymes responsible for dioxane biosynthesis were found to catalyze 
unusual reactions or to utilize uncommon reaction mechanisms. In fact, there are no 
previous mechanistic level studies related to the rare C-ribosylation catalyzed by AlnA. 
The apparently cofactorless enzyme Aln6, in turn, was found to convert the ribose unit of 
the pathway intermediate alnumycin C into the rare dioxolane unit of the next pathway 
intermediate, alnumycin B, via a mechanism that involves the consumption of molecular 
oxygen coupled to the formation of hydrogen peroxide. Finally, the deduced aldo-keto 
reductase Aln4 was found to catalyze not only the reduction of an aldehyde to an alcohol, 
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but also the reductive conversion of the dioxolane unit to the dioxane unit of the pathway 
end product alnumycin A (Fig. 13). 
Characterization of the novel dioxane pathway illustrates how unique sugar mimicking 
units can be made from simple sugar-5-phosphate precursors, and the knowledge gained 
on the biosynthetic steps and enzymes might be applicable for drug discovery purposes. 
The usefulness of the dioxane biosynthetic enzymes in the generation of novel compounds 
with C–C bound ribose, dioxolane and dioxane moieties is currently under investigation 
in a follow-up study in our laboratory. In addition, a collaborative study on the biological 
activities of the novel natural products, that were isolated and characterized during the 
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